Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Organogenesis Holdings (ORGO) Cost of Revenue (2017 - 2025)

Organogenesis Holdings (ORGO) has 9 years of Cost of Revenue data on record, last reported at $64.4 million in Q4 2025.

  • For Q4 2025, Cost of Revenue fell 33.83% year-over-year to $64.4 million; the TTM value through Dec 2025 reached $214.6 million, up 5.55%, while the annual FY2025 figure was $214.6 million, 5.55% up from the prior year.
  • Cost of Revenue reached $64.4 million in Q4 2025 per ORGO's latest filing, up from $53.2 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $97.3 million in Q4 2024 and bottomed at $23.7 million in Q1 2025.
  • Average Cost of Revenue over 5 years is $37.2 million, with a median of $27.4 million recorded in 2022.
  • Peak YoY movement for Cost of Revenue: soared 250.45% in 2024, then tumbled 33.83% in 2025.
  • A 5-year view of Cost of Revenue shows it stood at $32.6 million in 2021, then fell by 16.83% to $27.1 million in 2022, then rose by 2.43% to $27.8 million in 2023, then skyrocketed by 250.45% to $97.3 million in 2024, then plummeted by 33.83% to $64.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $64.4 million in Q4 2025, $53.2 million in Q3 2025, and $73.3 million in Q2 2025.